Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody

We report a case of a 38-year-old woman who was diagnosed with stage IV lung adenocarcinoma, harboring an epidermal growth factor receptor (EGFR) L858R mutation on exon 21 and a T790 M mutation on exon 20. The patient was treated with osimertinib, a third-generation EGFR tyrosine kinase inhibitor (E...

Descripción completa

Detalles Bibliográficos
Autores principales: Mamesaya, Nobuaki, Kenmotsu, Hirotsugu, Katsumata, Mineo, Nakajima, Takashi, Endo, Masahiro, Takahashi, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306260/
https://www.ncbi.nlm.nih.gov/pubmed/27599705
http://dx.doi.org/10.1007/s10637-016-0389-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306260/
https://www.ncbi.nlm.nih.gov/pubmed/27599705
http://dx.doi.org/10.1007/s10637-016-0389-9

Ejemplares similares